US4147768A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Enteric coated digoxin and therapeutic use thereof
Assignee: Interx Research Corp
•
Filing: 1978-05-19
•
Granted: 1979-04-03
•
Expires: 1998-05-19
Abstract
Abstract Therapeutic and undegraded levels of digoxin in warm-blooded animals are achieved by orally admininstering thereto, a non-toxic pharmaceutical enteric-coated tablet comprising: (a) A cardiotonic effective amount of digoxin; (b) a non-toxic pharmaceutically acceptable inert diluent, and (c) a standard non-toxic pharmaceutically acceptable enteric coating. This composition is extremely useful in the treatment of cardiac insufficiency in warm-blooded animals. When administered to warm-blooded animals (e.g., humans), superior therapeutic and undegraded blood levels of digoxin are observed over that normally observed with conventional solid dosage formulations for oral administration.
Inventors
- 👤 Richard D. Shaffer
- 👤 John J. Windheuser
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 01:59
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/20; A61K9/28; A61K9/2806; A61K9/2833; A61K9/286; A61K9/2866; A61K31/00; A61K31/70; A61K31/7042; A61K31/7048; A61K9/0002; A61K9/0007
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
67 words
A pharmaceutically acceptable enteric coated tablet for orally delivering therapeutic and undegradated levels of digoxin to a warm-blooded animal which comprises an admixture of: (a) a cardiotonic effective amount of digoxin; (b) a non-toxic pharmaceutically acceptable inert diluent; (c) a non-toxic pharmaceutically acceptable effervescent couple-acid and base; and (d) a standard non-toxic pharmaceutically acceptable enteric coating maintained over said tableted mixture of (a), (b) and (c) above.
Claim 2
Dependent Claim
67 words
A pharmaceutically acceptable enteric coated tablet for orally delivering therapeutic and undegradated levels of digoxin to a warm-blooded animal which comprises an admixture of: (a) a cardiotonic effective amount of digoxin; (b) a non-toxic pharmaceutically acceptable inert diluent; (c) a non-toxic pharmaceutically acceptable effervescent couple-acid and base; and (d) a standard non-toxic pharmaceutically acceptable enteric coating maintained over said tableted mixture of (a), (b) and (c) above.
Claim 3
Dependent Claim
24 words
The tablet of claim 1, wherein said enteric coating is a member selected from the group consisting of cellulose acetate phthalate and hydroxypropylmethylcellulose phthalate.
Claim 4
Dependent Claim
23 words
The tablet of claim 2, wherein said hydroxypropylmethylcellulose phthalate is a member selected from the group consisting of hydroxypropylmethylcellulose phthalate-45 and hydroxypropylmethylcellulose phthalate-50.
Claim 5
Independent Claim
70 words
A method for inducing therapeutic and undegradated levels of digoxin in a warm-blooded animal which comprises administering thereto, a pharmaceutically acceptable enteric coated tablet comprising an admixture of: (a) a cardiotonic effective amount of digoxin; (b) a non-toxic pharmaceutically acceptable inert diluent; (c) a non-toxic pharmaceutically acceptable effervescent couple-acid and base; and (d) a non-toxic pharmaceutically acceptable enteric coating maintained over said tableted mixture of (a), (b) and (c) above.
Claim 6
Independent Claim
70 words
A method for inducing therapeutic and undegradated levels of digoxin in a warm-blooded animal which comprises administering thereto, a pharmaceutically acceptable enteric coated tablet comprising an admixture of: (a) a cardiotonic effective amount of digoxin; (b) a non-toxic pharmaceutically acceptable inert diluent; (c) a non-toxic pharmaceutically acceptable effervescent couple-acid and base; and (d) a non-toxic pharmaceutically acceptable enteric coating maintained over said tableted mixture of (a), (b) and (c) above.
Claim 7
Dependent Claim
24 words
The method of claim 4, wherein said enteric coating is a member selected from the group consisting of cellulose acetate phthalate and hydroxypropylmethylcellulose phthalate.
Claim 8
Dependent Claim
23 words
The method of claim 5, wherein said hydroxypropylmethylcellulose phthalate is a member selected from the group consisting of hydroxypropylmethylcellulose phthalate and hydroxypropylmethylcellulose phthalate-50.
References Cited (Backward Citations)
US536155A
Cited
US1690760A
Cited
US2196768A
Cited
US2433244A
Cited
US2540979A
Cited
US2698822A
Cited
US2887440A
Cited
US3131123A
Cited
US3081233A
Cited
US3939259A
Cited
US3961041A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1982-04-02 | 1982-10-02 | 1983-04-03 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1986-04-02 | 1986-10-02 | 1987-04-03 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1990-04-02 | 1990-10-02 | 1991-04-03 | $7700.00 | Window Closed / Lapsed |